Last checked at 19 Feb 2021 12:31
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr J Ford | |||
b) | Position/status | SVP & General Counsel | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053 | |||
b) | Nature of the transaction | Following the vesting on 16 February 2021 of an award made on 6 September 2018 under the GlaxoSmithKline Deferred Investment Award programme in lieu of a Share Value Plan award, Mr Ford will receive a cash payment of $225,308 less applicable tax withholding in respect of 6,320 notional American Depositary Shares. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| $35.6500 | 6,320 |
| ||
|
|
|
| ||
d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2021-02-17 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms D Waterhouse | |||
b) | Position/status | CEO of ViiV Healthcare | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Following the vesting on 16 February 2021 of an award made on 16 February 2015 under the GlaxoSmithKline Deferred Investment Award programme in lieu of a Share Value Plan award, Ms Waterhouse will receive a cash payment of £194,803.33 less applicable tax withholding in respect of 15,302.697 notional Ordinary Shares. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £12.7300 . | 15,302.697 |
| ||
|
|
|
| ||
d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2021-02-17 | |||
f) | Place of the transaction
| N/A | |||